Cutaquig<sup>®</sup> Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
Objective: Subcutaneous immunoglobulin (SCIG) treatment is generally tolerable, but some patients may experience adverse events to one or more SCIG products. We investigated whether 16.5% Cutaquig<sup>®</sup> treatment offered a tolerable and safe alternative treatment for immunodeficient patients....
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI AG
2022-11-01
|
| 叢編: | Hematology Reports |
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/2038-8330/14/4/48 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|